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Background and Significance

Kalman, Morissette and George (2005), Am. J. Addict., 14: 106-123

• “Nicotine-dependent
individuals with a
comorbid mental illness
made up 7.1% of the
population yet
consumed 34.2% of all
cigarettes smoked in the
United States”

Grant, B.F. , Hasin, D.S., Chou, S.P., Stinson, F.S.& Dawson, D.A. (2004). Nicotine dependence and psychiatric
disorders in the United States: Results from a national epidemiologic survey on alcohol and related conditions. Archives
of General Psychiatry,61,1107-1115.

Individuals living with mental illnesses have higher
occurrences of tobacco caused mortality...
•In an 13 year follow-up of 370 individuals living with schizophrenia,
smoking related fatal diseases were more prominent than the general
population.
•Individuals living with severe mental illnesses (including schizophrenia,
bipolar disorder, and depression) lose 25 years or more of life expectancy
mostly related to cardiovascular disease
•Individuals with severe mental illness are three times more likely to die
from cardiovascular disease as compared to the general population

Brown, Barraclough, & Inskip (2000) Causes of the excess mortality of schizophrenia. British Medical Journal.
Newcomer et al (2007) Severe mental illness and risk for cardiovascular disease. JAMA.
Osborn et al. (2007). Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the
United Kingdom's General Practice Research Database. Arch Gen Psychiatry

Reasons for smoking among individuals living
with mental illnesses

• Genetic

• Biologic

• Psychosocial

Genetic Reasons: Mental health and smoking
(1,566 female twin pairs) average life
time daily cigarette consumption was
found to be associated with life time
prevalence of major depression,
suggesting that the relationship
between smoking and major
depression resulted solely from genes
which predispose to both conditions.
(8,169 male twins) shared
genetic disorders further
predispose to major
depression and nicotine
dependence.
Kendler KS, Neale MC, MacLean CJ, et al. Smoking and Major Depression: A Causal Analysis. Archives of General Psychiatry 1993;
50:36-43
Lyons M, Hitsman B, Xian H, et al. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine & Tobacco
Research 2008; 10:97 - 108

Genetic Reasons: Mental health and smoking

•

63% of the association between post traumatic stress disorder
and nicotine dependence co-morbidity was explained by
shared genetic effects.

Koenen KC, Hitsman B, Lyons MJ, et al. A Twin Registry Study of the Relationship Between Posttraumatic Stress Disorder and Nicotine
Dependence in Men. Archives of General Psychiatry 2005; 62:1258-1265

Genetic Reasons: Mental health and smoking

•

Found a group of candidate genes and individual genes
among individuals with schizophrenia which were significantly
linked to smoking behaviors.

Faraone et al. (2004). A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for
smoking in Schizophrenia families

Biologic reasons: Mental health and smoking
Postma et al.
Psychopharmacology (2006)
184: 589–599

nicotine reduces sensorimotor gating deficits in
smokers with schizophrenia

Barr, Culhane, Jubelt, et al.
Neuropsychopharmacology
2007; 33:480-490

administration of transdermal patch nicotine
improves attention and response inhibition in
nonsmokers with schizophrenia

Fowler, Volkow, Wang, et al.
Proceedings of the National
Academy of Sciences of the
United States of America
1996; 93:14065-14069

brain levels of monoamine oxidase A (MAO-A) (an
enzyme associated with depression) were reduced
in smokers relative to nonsmokers; suggesting that
people with affective disorders may smoke to
reduce elevated MAO-A levels in the brain

McCabe, Chudzik, Antony,
et al. Journal of Anxiety
Disorders 2004; 18:7-18

Smokers with a primary diagnosis of anxiety
disorder reported greater levels of general anxiety,
distress, and depression as compared to
nonsmokers.

Psychosocial reasons: Mental health and smoking
• History of tobacco use as a token economy-cigarettes used as a ‘reward’ for appropriate
behavior (i.e., smoking privileges)
• Smoking among clients and staff to encourage
‘socialization’

Kawachi I, Berkman L. Social ties and mental health. Journal of Urban Health 2001; 78:458-467
Lawn S. Cigarette smoking in psychiatric settings: occupational health, safety, welfare and legal concerns. Australian and New Zealand
Journal of Psychiatry 2005; 39:886-891
Keizer I, Eytan A. Variations in Smoking during Hospitalization in Psychiatric In-Patient Units and Smoking Prevalence in Patients and
Health-Care Staff. International Journal of Social Psychiatry 2005; 51:317-328
Morisano D, Bacher I, Audrain-McGovern J, et al. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive
disorders. Canadian Journal Of Psychiatry. Revue Canadienne De Psychiatrie 2009; 54:356-367

Arguments for Not Providing Tobacco Treatment….

“these patients don’t want to quit”
• In a review of 9 studies of motivation to quit smoking among
individuals with psychiatric disorders at least 50% are
contemplating cessation
(Siru, Hulse & Tait, 2009).

“these patients are unable to quit”
• Recent study found end-of-treatment smoking cessation rates of
20% among individuals with psychiatric disorders accessing
outpatient tobacco treatment program
(Selby et al, 2010)

• Another recent study found end-of-treatment smoking cessation
rates of 22.4% and smoking reduction of over 50% among
participants in a smoking cessation program for individuals living
with severe and persistent mental illness
(Masahura, Heah, and Okoli, 2012- under review)

Smoking cessation medications

Longer treatment duration
100

Smoking Cessation by length of stay in the program (n = 678)*
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* Statistically significant differences between groups

Important considerations of smoking cessation for
individuals living with mental illnesses
• Concerns that smoking cessation will increase psychiatric symptoms
or relapse among patients.
o Among individuals with depression, smoking cessation related to increased
depression symptomatology, which is one of the symptoms of the nicotine
withdrawal syndrome
o individuals with anxiety disorders and depression report more severe
withdrawal symptoms
o smoking is associated with improvements in prepulse inhibition and sensory
gating which may be affected by smoking cessation

Patten C, Martin J. Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Annals of Behavioral Medicine 1996; 18:190-200
Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. American Journal of Psychiatry 1992;
149:464-469
Adams CE, Stevens KE. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Frontiers in Bioscience 2007; 12:4755-4772
Kumari V, Postma P. Nicotine use in schizophrenia: The self medication hypotheses. Neuroscience & Biobehavioral Reviews 2005; 29:1021-1034
el-Guebaly N, Cathcart J, Currie S, et al. Public health and therapeutic aspects of smoking bans in mental health and addiction settings. Psychiatr Serv 2002; 53:1617-1622
Ziedonis DMa, Williams JMb. Management of smoking in people with psychiatric disorders. Current Opinion in Psychiatry 2003; 16:305-315

Costs associated with smoking cessation treatment
• Even though less expensive than purchasing cigarettes, the cost of
pharmacotherapy and counseling presents an important barrier to
seeking treatment
• Such cost barriers to accessing treatment and the potential costeffectiveness of treatment have prompted guidelines about
reducing medication costs (reduced cost or free of charge),
inclusion of medications as benefits on drug insurance plans, and
setting up systems for reimbursement for tobacco cessation
treatment for health care providers.
Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them?
Nicotine & Tobacco Research 2004; 6:303-310
Reilly P, Murphy L, Alderton D. Challenging the smoking culture within a mental health service supportively. International Journal of Mental Health
Nursing 2006; 15:272-278
Fiore M, Jaén C, Baker T, et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service
Report. American Journal of Preventive Medicine 2008; 35:158-176
Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. British Medical Journal 1999; 318:182-185
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